In 2013, Liverpool Heart and Chest Hospital NHS Foundation Trust became one of the first trusts nationally to introduce Sunrise Electronic Patient Record (EPR). Since then, it has continued making strides in its digital journey: optimising and enhancing the EPR with documentation and tracking board enhancements and embedded decision support, integrating clinical systems, embedding information sharing across care services, and investing in digital infrastructure, cybersecurity and intelligence-led care. With a steadfast focus on patient safety, LHCH clinicians shape its EPR and digitisation initiatives using technology to reduce risk, improve efficiency and deliver the highest quality care. In just a few years, LHCH has become 99.9% paperless. It has also been ranked third in Cheshire and Merseyside for digital maturity and was rated “Outstanding” by the Care Quality Commission, which was the first time a specialty trust earned this rating. LHCH is currently top in the country in the Care Quality Commission’s National Inpatient Survey, which is the ninth time LHCH has earned this distinction in the last 12 years.

Join this webinar to learn more about how the trust:

• Adopted digital excellence and continually look to improve care
• Became top-rated for digital maturity and achieved HIMSS EMRAM Stage 6
• Transformed into a nearly 100% paperless hospital
• Identified clinical leadership as being one of the key factors in its EPR success
• Implemented closed loop medication administration
• Continues to further pioneer innovation and advance use of technology to become an EMRAM Stage 7 hospital in the near future

Read on digitalhealth.net

The concept of a rapid learning health system (LHS) has matured since the mid-2000s, and is now an integral element of many academic medical centers and health care delivery systems. Given the complexity of health and health care, fully realizing the LHS requires diverse, multidisciplinary competencies, including expertise in systems science, engagement, leadership, and informatics. Additionally, those seeking to bring the LHS from concept to reality must be knowledgeable about a range of research and analytic methods, skillful in the development and implementation of research in real-world settings, and uphold an abiding commitment to health equity and justice in the context of care delivery.  These and other domains have been the backbone of LHS training programs, including longstanding training opportunities in the VA health system, newer programs in forward-looking health systems, and in organizations that received funding from the AHRQ-PCORI's Learning Health Systems Researcher Training Program. This 60-minute webinar offers an opportunity to hear from three eminent LHS research leaders who have led these training initiatives, and will also include an overview the recent LHS Interest Group Challenge Contest. 

Read on academyhealth.org

With next generation of complex immuno-oncology candidates, preclinical and translational scientists in the IO space are in need for more predictive tumour models to improve clinical translatability, accelerating speed-to-clinic with confidence.

We are excited to finally reunite this community in December at 11th PREDiCT: Tumour Models London Summit to address the critical next step of narrowing the preclinical gap and progressing efficacious candidates to the clinic.

This much-anticipated in-person meeting will unite 120+ pioneers to help you:

Benchmark against peers' in vivo and in vitro model selection strategy for novel IO, in conjunction with NK and macrophages interaction with TME, to maximise translatability

Evaluate and compare next generation tumour models for TME, cell-cell interaction, immune response and drug response to guide clinical design and patient selection

Accelerate off-the-shelf humanised and PDX model development for NK, allogenic cell therapies

Rigorously test, characterise, validate novel cancer models to support adoption and ensure quality control in preclinical studies

Engage with leading academics and CROs to drive long-term partnerships and fuel model innovations

This is your must-attend tumour model summit to reconnect with fellows from Pfizer, Sanofi, GSK, and propel your clinical progression with confidence in 2023!

Companies are choosing to invest heavily to build in-house capabilities to leverage RWE efficiently. But questions remain, especially for organizations that are just beginning to apply RWE. How can RWE be made more accessible to stakeholders across the enterprise? What are the most practical applications of RWE to accelerate research and commercialization? And, how will pharma continue to utilize RWE as an end-to-end capability to improve outcomes and meet business goals? Two pharma giants, Pfizer and Boehringer Ingelheim, have built RWE centers of excellence (CoE), acting as the heart of real-world data (RWD) and RWE for the broader organization. These CoEs house RWE experts and support the clinical and commercial teams to achieve their goals.

Read on xtalks.com

Expect an evening of dynamic speakers, strategic deep dives, and industry insights from our expert lineup. Please find speaker bios below. The event will focus on the challenges and opportunities of this exciting next step in healthcare. We will also be joined by Venture Lab NGK SPARK PLUG, CO., LTD. portfolio company partners who will share the latest developments and product demonstrations of their groundbreaking technology.

Read on eventbrite.com

The strengths and challenges to providing MOUD in each community and clinic vary. This session will discuss the role that telemedicine can play in expanding access to MOUD in rural communities. Telemedicine can be provided by rural clinics themselves, or by external telemedicine providers to whom a rural clinic refers some or all of its patients with OUD. Through case examples, the presenters will highlight how telemedicine has been used to improve access to initiating and maintaining MOUD in rural communities, and share experiences using telemedicine approaches. 

Read on uclahs.zoom.us

This event connects you with public and private payers for direct perspective into policy development and decision-making frameworks so you can successfully expand product coverage. Avoid pitfalls and improve market access through lessons learned, and collaborate on solutions during Q&A after peer-led case studies and success stories. Develop relationships with decision-makers as well as diagnostic industry peers in interactive discussion-based sessions. Through dynamic presentations from these commercial payer organizations as well as laboratories, test manufacturers, law firms and solution providers, learn in an intimate environment. Retain expert insights and address your individual questions on policy and coverage decisions so you can perfect your strategy to optimize reimbursement.

Read on q1productions.com

N-Nitrosamine impurity findings in marketed formulations of rifampin have disrupted drug development. As a strong cytochrome P450 3A4 (CYP3A4) inducer, rifampin was regularly co-administered with investigational products during pharmacokinetic drug-drug interaction studies. However, due to recent impurity issues, its application in these studies has been suspended in both the US and EU. This webinar will examine the root cause of rifampin impurity and describe the industry and regulatory response to this issue. In addition, the featured speakers will address alternative approaches and CYP3A inducers to encourage the continuation of drug-drug interaction studies and drug development.

N-Nitrosamines are a class of chemicals recognized as a “cohort of concern” due to their mutagenic and carcinogenic potential. Typically, levels above an acceptable intake limit may lead to a probable or possible risk of cancer in humans. Rifampin capsules were found to contain 1-methyl-4-nitrosopiperazine (MNP) above the acceptable intake limit of 0.16 ppm. However, it’s important to note that nitrosamines are not limited to drug products, and low levels can be found in drinking water, processed meats and tobacco exposure. Therefore, in theory, a diet low in nitrosamines could offset any potential exposure during rifampin drug-drug interaction studies.

Read on xtalks.com

This course is aimed at residents in their 4th and 5th year of training in radiology and recently board-certified radiologists interested in Musculoskeletal Radiology. It is strictly adhered to Level II of the European Training Curriculum. The course includes six topics consisting of 40 minutes of theory and case presentations followed by a live Q&A section after each session for interaction with the faculty members.

Read on connect.myesr.org

The medical technology industry becomes an essentiel component of the whole care pathway. Advanced technologies such as Smart connectivity, Health Sensors, AI/ML in decision making, robotics, VR/AR/XR are not only improving medical devices but also are opening new perspectives for the care of human beings. According to « Absolute Markets Insights ». Global medical technology market was valued at US$ 565,52 billion in 2018 and is expected to reach 2324.34 billion by 2027, growing at an estimated CAGR of 17.1% over the forecast period. The segments that we will develop in this conference are about the use of solutions in the field of of mHealth, eHealth, telemedicine, telematics / telemetry, medical information systems / software, Medical Apps, portable diagnostics, wearables and augmenting human features and well beings.

Read on net-must.com